Rimiducid is named as an intervention in 7 current clinical trials in our USA and China registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Poseida Therapeutics, Inc (3). The most-studied condition is Myelodysplastic Syndromes.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
NCT07598955 · ClinicalTrials.gov ↗ · B2 Thymoma, Thymic Carcinoma
|
Phase 1/2 | Recruiting | Beijing Biotech | China |
|
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
NCT01744223 · Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma
|
Phase 1/2 | Active, closed | Bellicum Pharmaceuticals | USA |
|
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
NCT03301168 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin
|
Phase 1/2 | Active, closed | Bellicum Pharmaceuticals | USA |
|
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
NCT02477878 · ClinicalTrials.gov ↗ · Leukemia, Myelodysplastic Syndromes, Lymphoma
|
Phase 1 | Active, closed | Bellicum Pharmaceuticals | USA |
|
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
NCT04960579 · ClinicalTrials.gov ↗ · Multiple Myeloma
|
Phase 1 | Active, closed | Poseida Therapeutics, Inc. | USA |
|
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT05239143 · Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer
|
Phase 1 | Active, closed | Poseida Therapeutics, Inc. | USA |
|
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
NCT06014762 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
|
Phase 1 | Active, closed | Poseida Therapeutics, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Myelodysplastic Syndromes | 3 |
| Acute Lymphoblastic Leukemia | 2 |
| Lymphoma | 2 |
| Multiple Myeloma | 2 |
| Breast Cancer | 1 |
| Ovarian Cancer | 1 |
| Non Small Cell Lung Cancer | 1 |
| Colorectal Cancer | 1 |
| Acute Myelogenous Leukemia | 1 |
| Leukemia, Acute Myeloid (AML), Child | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Leukemia | 1 |
| Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 |
| High-grade B-cell Lymphoma | 1 |
| Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 1 |
| Transformed Follicular Lymphoma (tFL) | 1 |
| B2 Thymoma | 1 |
| Thymic Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Poseida Therapeutics, Inc. | 3 |
| Bellicum Pharmaceuticals | 3 |
| Beijing Biotech | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 6 | 0 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our USA and China registers name Rimiducid (also registered as AP1903) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 7 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Poseida Therapeutics, Inc (3), Bellicum Pharmaceuticals (3) and Beijing Biotech (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rimiducid works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Rimiducid works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rimiducid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.